8-K: Bone Biologics Faces Nasdaq Delisting Threat Due to Low Share Price

Bone Biologics Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• Bone Biologics Corporation received a notification from Nasdaq on April 7, 2025, stating that it no longer meets the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).
• The company has a 180-day compliance period, until October 6, 2025, to regain compliance by maintaining a closing bid price of at least $1 per share for a minimum of 10 consecutive business days.
• Failure to regain compliance could result in delisting, which the company could appeal.
• Bone Biologics intends to monitor its stock price and consider options, including seeking stockholder approval for a reverse stock split at its upcoming annual meeting.
• The Board of Directors may authorize a reverse stock split to increase the share price if stockholders approve the proposal and the share price remains below $1.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial distress and potential challenges for the company. However, the company is taking steps to address the issue, which provides a slight offset.

Positives

• The company has a 180-day period to regain compliance with Nasdaq listing rules.
• The company is considering a reverse stock split to increase the share price.

Negatives

• The company's common stock has been trading below the minimum bid price of $1 per share for 30 consecutive business days.
• Failure to regain compliance could lead to delisting from the Nasdaq Capital Market.

Risks

• The company may not be able to regain compliance with the Nasdaq listing standards.
• A reverse stock split may not be approved by stockholders or may not be effective in increasing the share price.
• Delisting from Nasdaq could negatively impact the company's stock price and ability to raise capital.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider its available options, including a potential reverse stock split, to regain compliance with Nasdaq listing standards.

Management Comments

• The Company intends to seek stockholder approval for a reverse stock split of its outstanding common stock at its upcoming annual meeting of stockholders.
• If the closing bid price of the common stock remains below $1 per share and the stockholders approve the proposal, the Company's Board of Directors may authorize a reverse stock split to attempt to increase the per share price of the common stock and regain compliance with the Nasdaq Listing Standards.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and market conditions. Reverse stock splits are a common strategy employed to artificially inflate the share price and meet minimum bid requirements.

Comparison to Industry Standards

• Other companies facing similar delisting notices often explore options like reverse stock splits, attracting new investors, or seeking alternative exchanges.
• The success of a reverse stock split in maintaining listing status varies, with some companies experiencing a temporary increase in share price followed by further decline.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Monitor the closing bid price of the common stock.
• Consider available options to regain compliance with Nasdaq listing standards.
• Seek stockholder approval for a reverse stock split at the upcoming annual meeting.
• The Board of Directors may authorize a reverse stock split.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, reverse stock split, compliance, Bone Biologics, stock price